Selskabets formål er at drive virksomhed inden for den farmaceutiske, biotekniske og medicinske produktionsindustri, herunder men ikke begrænset til kliniske forsøg, samt anden hermed forbundet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 35 mio. | 1.3 mio. | 48.3 mio. | 19 mio. | 0 | |
CVR: 31588626
Compared to 1.508 companies in Administrations- og kontorserviceaktiviteter
Comparison is based on industry median values
The financial health of PAREXEL DENMARK A/S shows signs of stability, with a slight decline in revenue from 39.83 million DKK in 2022 to 34.98 million DKK in 2025. Profitability has fluctuated, peaking at 2.33 million DKK in 2024 but dropping to 1.29 million DKK in 2025, indicating potential challenges in maintaining margins. Equity has steadily increased from 12.23 million DKK in 2021 to 19.05 million DKK in 2025, suggesting a strengthening balance sheet. Overall, while the company remains positioned within the administrative services sector, its recent revenue trends and profit volatility may warrant closer scrutiny for future growth prospects.
AI-generated summary
Companies in the same industry and area
CVR 10531047
CVR 46291263
CVR 32470505
CVR 44225565
CVR 43194569
companydata.dk